To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evaluated AE data from four multiple-dosage Phase I trials (duration: 8-34 days). Therapeutic (20 and 40 mg/day) and supratherapeutic clobazam dosages (120 and 160 mg/day) were administered. Adverse events (AEs) were also assessed for patients with Lennox-Gastaut syndrome enrolled in Phase II (OV-1002) and Phase III (OV-1012) studies (duration ≤ 15 weeks) and in the open-label extension (OLE) trial OV-1004 (≤5 years). Potential withdrawal-related AEs were identified by preferred terms, provided that the AEs occurred ≥1 day following and ≤30 days after the last clobazam doses, or were deemed withdrawal symptoms by investigators. Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) scale was used to evaluate withdrawal intensity in three of the four Phase I trials. A total of 207 participants in Phase I trials received steady-state clobazam dosages of 20-160 mg/day, 182 received clobazam dosages of ≥40 mg/day, and 94 received clobazam dosages of ≥120 mg/day. Abrupt clobazam discontinuation led to 193 withdrawal-related AEs for 68 Phase I participants. Nearly 50% of AEs occurred after discontinuation of clobazam dosages of ≥120 mg/day. Adverse events were mild or moderate and included headache (14% of Phase I participants), insomnia (12.6%), tremor (10.1%), and anxiety (8.7%). The CIWA-B scores varied (range: 0-59). Most scores were b30, indicating possible mild benzodiazepine withdrawal. III trials met the criteria for potential/III patients received clobazam dosages of ≤40 mg/day, and those in the OLE trial received clobazam dosages of ≤80 mg/day. Eighty-seven patients discontinued clobazam and were gradually tapered. No withdrawal-related AEs or incidences of status epilepticus were reported. Withdrawal-related AEs observed in Phase I studies following abrupt clobazam discontinuation at therapeutic and supratherapeutic dosages were generally mild. No withdrawalrelated AEs occurred when dosages were tapered over 3 weeks, after short-or long-term clobazam use (≤5 years).
Introduction
Lennox-Gastaut syndrome (LGS), a severe childhood epileptic encephalopathy, is characterized by slow spike-and-wave electroencephalograms, as well as by occurrence of several seizure types including tonic, atonic, and atypical absence [1] . Most patients with LGS have chronic, treatment-refractory epilepsy throughout childhood and adolescence. Abnormal mental development and behavioral disturbances are common in these patients, and most experience continued neurocognitive impairment that persists into adulthood.
The 1,5-benzodiazepine clobazam (Onfi®) was approved in 2011 by the US Food and Drug Administration as adjunctive treatment for seizures associated with LGS for patients 2 years of age and older [2] . Efficacy and safety of clobazam in patients with LGS have been established in III trials met the criteria for potential/III trials [3] [4] [5] [6] . Outside the United States, clobazam has been used to treat anxiety disorders and epilepsy for several decades [2] .
The abrupt discontinuation of benzodiazepines often results in a spectrum of adverse events (AEs) related to withdrawal [7] [8] [9] . These symptoms often include anxiety, insomnia, irritability, sedation, seizures, and somnolence. To determine the potential withdrawal-related adverse events (AEs) of clobazam, we evaluated data from Phase I trials (during which clobazam dosages were abruptly discontinued) and III trials met the criteria for potential/III epilepsy trials (during which clobazam dosages were tapered gradually).
Methods
Potential withdrawal-related AEs following abrupt clobazam discontinuation in four Phase I trials or gradual tapering in three III trials met the criteria for potential/III clobazam trials were assessed. The trials are summarized below.
Phase I trials (abrupt clobazam discontinuation)

OV-1022
This thorough cardiac conduction (T-QT) study was double-blind, double-dummy, randomized, single-site, 4-arm, and parallel-group in design. The objective of this trial was to examine the potential of clobazam and its primary active metabolite, N-desmethylclobazam (N-CLB), to have clinically significant effects on cardiac intervals at both therapeutic (40 mg/day) and supratherapeutic (160 mg/day) dosages compared with moxifloxacin (400 mg/day, active control) and placebo. The QT interval is the time between the start of the Q-wave and the end of the T-wave on an EKG.
A total of 280 healthy male and female volunteers were enrolled and divided among the four groups. Treatments were administered under fasting conditions from Days 1 through 29 and discontinued abruptly (no tapering of dosage).
OV-1023
This open-label, multiple-dosage, drug-interaction study assessed the safety, tolerability, and single-dose pharmacokinetics (PK) profiles of a drug cocktail containing midazolam (4 mg), caffeine (200 mg), tolbutamide (500 mg), and dextromethorphan (30 mg), following multiple clobazam dosages. The drug cocktail represents agents that are substrates of certain cytochrome P450 isoenzymes.
A total of 18 healthy male volunteers were enrolled and administered the drug cocktail on the morning of Day 1. Oral clobazam (40 mg) was then administered once daily on Days 4-18, and then a single oral dose of clobazam (40 mg) was coadministered with a single oral dose of the drug cocktail on Day 19 before treatment was discontinued.
OV-1032
The objective of this Phase 1, open-label, multiple-dosage study was to examine the effects of impaired renal function (mild and moderate) on the PK profile of clobazam. Seven participants with mild and six participants with moderate renal impairment (based on estimated creatinine clearance [CL CR ] N 50-80 mL/min and CL CR 30-50 mL/min, respectively) and 12 control participants with normal renal function (CL CR N 80 mL/min) were enrolled. Healthy participants were matched to those with renal impairment at the same centers on the basis of age, race, sex, weight, and smoking status. All participants received a single 20-mg dose of clobazam on Day 1 and once-daily clobazam on Days 5-11. Participants fasted overnight prior to study drug administration each morning.
OV-1038
This open-label, single-center, multiple-ascending-dosage study was designed to evaluate the safety, tolerability, and the steady-state PK profile of clobazam in healthy adult participants. Twenty-four participants (male or female) were enrolled and assigned to one of two treatment groups. Data from Group 1 were used to establish the maximum-tolerated-titrated dosage, defined as the greatest dosage in excess of 60-mg/day tolerated-titrated dosage that was tolerated for 3 consecutive days by at least 70% of the individuals who had previously tolerated 60-mg/day tolerated-titrated dosage.
Study medication was administered twice daily under fasting conditions. In Group 1, clobazam was titrated from 10-mg/day toleratedtitrated dosage to 160-mg/day tolerated-titrated dosage, with each dosage administered for at least 3 days prior to dosage increase. The tolerated-titrated dosage was increased by 10-mg/day through 60-mg/day tolerated-titrated dosage and then by 20 mg/day until either 160-mg/day tolerated-titrated dosage was reached or the dosage was deemed intolerable (which included, but was not limited to, assessment by scales and AE monitoring) by investigators. Clobazam administration was concluded with a single morning dose of the maximum tolerated-titrated dosage (80 mg).
In Group 2, dosage titration was performed in a manner similar to Group 1, with the greatest scheduled dosage of 140-mg/day tolerated-titrated dosage. However, based on preliminary safety and PK assumptions, the greatest dosage administered in Group 2 was 120-mg/day tolerated-titrated dosage. Once participants had been titrated to 120-mg/day tolerated-titrated dosage and demonstrated tolerability for 3 days, they then received 120-mg/day tolerated-titrated dosage for an additional 11 days, followed by a final morning dose of 60 mg.
III trials met the criteria for potential/III trials (gradual clobazam tapering)
In trials OV-1002, OV-1012, and OV-1004, patients who discontinued were gradually tapered off clobazam.
OV-1002 and OV-1012
Trial OV-1002 was a Phase II, multicenter, randomized, doubleblind, dosage-ranging, parallel-group study designed to assess the efficacy and safety of clobazam as adjunctive therapy to a stable regimen of antiepileptic drugs (AEDs) in patients 2-30 years of age with LGS [3] . The study consisted of a 4-week baseline period, a 3-week titration period, a 4-week maintenance period, and a 3-week taper period, with a final visit 1 week after last dose for patients not continuing in the openlabel extension (OLE) study OV-1004.
The Phase III OV-1012 trial (also known as CONTAIN 4 ) was a multicenter, randomized, double-blind, placebo-controlled study that assessed the efficacy and safety of clobazam as adjunctive therapy to a stable AED regimen in patients 2-60 years of age with LGS [4] . The study included a 4-week baseline period, a 3-week titration period, and a 12-week maintenance period, followed by either continuation in the OV-1004 OLE or a 2-to 3-week taper period (depending on patients' weights), with a follow-up visit 1 week after the last clobazam dose.
In trial OV-1002, patients were randomly assigned to low-dosage clobazam (0.25 mg/kg up to a maximum daily dosage of 10 mg/day) or high-dosage clobazam (1.0 mg/kg, up to a maximum daily dosage of 40 mg/day). In trial OV-1012, patients were randomly assigned to placebo, low-dosage clobazam (0.25 mg/kg/day, maximum daily dosage of 10 mg/day), medium-dosage clobazam (0.5 mg/kg/day, maximum daily dosage of 20 mg/day), or high-dosage clobazam (1.0 mg/kg/day, maximum daily dosage of 40 mg/day). For both trials, study medication was administered twice daily. During titration, clobazam was initiated at either 5 mg/day or 10 mg/day. Dosages were then increased every 7 days until assigned target dosages were attained. Clobazam was administered twice daily. Investigators could decrease daily clobazam dosages by a single tablet (placebo or clobazam dosage of 5 mg/day) if a patient developed signs or symptoms of drug intolerance. The minimum clobazam dosage was 5 mg/day.
OV-1004
Patients from trials OV-1002 and OV-1012 were given the option of enrolling in OV-1004, a multicenter, OLE study of clobazam as adjunctive therapy in patients with LGS [5, 6] . The objective of this OLE trial was to collect safety and efficacy information regarding long-term clobazam usage in patients with LGS.
At the initiation of this OLE trial, all patients were started at a dosage of clobazam 0.5 mg/kg. Clobazam was given twice daily and the maximum allowed daily dosage was 2.0 mg/kg/day (maximum daily dosage of 80 mg/day). Investigators were allowed to initiate, adjust, and discontinue other AEDs and other forms of treatment to optimize patient care. During the first 4 weeks of the OLE trial, dosages were titrated to efficacy. Rescue medications were permitted no more than once per month. Upon completion of treatment, patients either continued commercially available clobazam or discontinued clobazam through a maximum 3-week taper period.
Analysis 2.3.1. Withdrawal-related adverse events
For the Phase I-III clobazam studies, potential withdrawal-related AEs were identified in the clinical trial safety database if they met the following criteria: 1) AE preferred term was in the potential withdrawal-related search term list in the database (Table 1) and 2) AE start date occurred at least 1 day following the last dose of clobazam and within 30 days after the last dose of study drug, or the AE was assigned by the principal investigator as a symptom of withdrawal. Potential withdrawal-related AE data were obtained from III trials met the criteria for potential/III studies from patients who had completed or discontinued the trials.
Clinical Institute Withdrawal Assessment for Benzodiazepines (CIWA-B) scale
The CIWA-B scale (Appendix A) was administered before dosing, during dosing, daily from the last day of dosing until the patient completed or discontinued the study and ad hoc at the investigators' discretion during Phase I studies OV-1022, OV-1023, and OV-1038. The CIWA-B scale evaluates benzodiazepine withdrawal using 20 five-point items [10] . The first three items (restlessness, tremor, and sweating) are evaluated by an observer, and the remaining 17 items are answered by the patients. The CIWA-B scores range from 0 to 80; scores ≤ 20 are indicative of possible mild benzodiazepine withdrawal.
Results
Discontinuations in multiple-dosage Phase I and III trials met the criteria for potential/III trials
A total of 207 of 347 participants in the four Phase I studies received multiple clobazam dosages (range: 20 to 160 mg/day) and were abruptly discontinued from the drug ( Table 2) . None of the participants who received moxifloxacin or placebo were included in this analysis. In the two double-blind III trials met the criteria for potential/III trials and the OLE trial, 33 (13%) and 54 (20%) patients, respectively, discontinued clobazam treatment. For all discontinuing patients in the III trials met the criteria for potential/III trials, clobazam dosages were gradually tapered over a maximum of 3 weeks.
3.2. Incidence of potential withdrawal-related adverse events in Phase I and III trials met the criteria for potential/III studies Of the 294 individuals who discontinued clobazam, 68 (32.9%) of the 207 participants in the Phase I trials experienced 193 potentially withdrawal-related AEs (Table 3) . No patients who discontinued from the Phase II/III trials experienced potentially withdrawal-related AEs. These AEs were mild or moderate, and the most commonly reported events overall included headache (14.0%), insomnia (12.6%), tremor (10.1%), and anxiety (8.7%). Moreover, no participants reported withdrawal-related seizures. The majority of AEs (110 of 193, 57%) were reported within 7 days after the last clobazam dose. Per protocol, 18 participants in trial OV-1022 (10 in the 40-mg/day tolerated-titrated dosage group and 8 in the 160-mg/day tolerated-titrated dosage group) and five participants in trial OV-1038 (3 in the 120-mg/day toleratedtitrated dosage group and 2 in the 160-mg/day tolerated-titrated dosage group) were treated with lorazepam and/or diazepam to manage withdrawal symptoms. The onset of withdrawal-related AEs following clobazam discontinuation treated with lorazepam and/or diazepam ranged from 2 to 19 days. Fifteen of the 193 AEs were managed with concomitant medications such as acetaminophen, loperamide, sleep aids, and propranolol. Status epilepticus was not observed following patient discontinuation in the Phase II/III trials.
CIWA-B scale
Three Phase I trials included the CIWA-B scale as an outcome. In trial OV-1022, the CIWA-B scores ranged from 0 to 56 (Fig. 1) . Ten and 12 participants in the clobazam 40-mg/day tolerated-titrated dosage and 160-mg/day tolerated-titrated dosage groups, respectively, had CIWA-B scores N 20. Further, five participants in the placebo group and six in the moxifloxacin group also had CIWA-B scores N 20. One participant each in the 40-mg/day tolerated-titrated dosage and 160-mg/day tolerated-titrated dosage groups had CIWA-B scores N 40. Of these participants, two in the clobazam 40-mg/day tolerated-titrated dosage group and one in the clobazam 160-mg/day tolerated-titrated dosage group experienced AEs related to withdrawal.
Although withdrawal-related AEs were reported for four participants in trial OV-1023, only three had CIWA-B scores N 20 (maximum value of 27) at any time during the study (Fig. 1) . In trial OV-1038, of participants who received clobazam 120 mg/day, all but one participant had CIWA-B scores ≤ 20. One participant had a CIWA-B score of 23 in the clobazam 120-mg/day group. Of participants in the clobazam 160-mg/day group, only one participant had a CIWA-B score N 20 at any time during the study. In addition, one participant had a CIWA-B score of 59 in the clobazam 160-mg/day group.
For all three trials, no correlations between CIWA-B scores and withdrawal-related AEs were observed.
Discussion
This article describes withdrawal-related AEs following abrupt clobazam discontinuation (Phase I trials, 207 participants) and gradual clobazam tapering (Phase II/III trials, 87 patients with LGS). Understanding the effects of AED withdrawal is a key clinical issue for physicians caring for patients with LGS and other epilepsies. Of all the data evaluated, only participants in the Phase I trials experienced potentially withdrawal-related AEs. Although multiple therapeutic and supratherapeutic clobazam dosages were administered in these trials, the incidences of withdrawal-related AEs were similar. The most commonly reported withdrawal-related AEs were consistent with those observed following benzodiazepine discontinuation [7] [8] [9] . None of the events were severe, and all resolved. Notably, the 2-to 3-week gradual tapering used in the Phase II/III trials was more rapid than typical clinical practice, yet none of the patients who discontinued the Phase II/III trials met the criteria for potentially withdrawal-related AEs. The results show that gradual clobazam tapering may lessen the potential for withdrawal-related AEs, as opposed to abrupt discontinuation.
The CIWA-B scale is used to evaluate the overall degree of benzodiazepine withdrawal symptoms. Given that 17 of the 20 questions used to evaluate the CIWA-B scores are self-rated, score variability is likely. Indeed, this was observed in the three Phase I clobazam trials presented in this article, for which the CIWA-B scores ranged from 0 to 59. Participants with scores ≤ 20 are considered to have possible mild benzodiazepine withdrawal. Although scores ranged from 0 to 56 in the placebocontrolled trial OV-1022, a handful of clobazam-treated participants had CIWA-B scores N 20. Furthermore, the numbers of participants with CIWA-B scores N 20 in both the therapeutic and supratherapeutic clobazam dosage groups were similar to scores for those participants who did not receive clobazam. The greatest CIWA-B score in all three trials (59) was reported in trial OV-1038 by one participant at a single study visit. All other CIWA-B scores evaluated for this participant were ≤20. Despite the absence of a trend or correlation between these scores and withdrawal-related AEs, the CIWA-B scores were useful in determining the intensity of withdrawal-related AEs in the three Phase I trials. To counter the variability in the CIWA-B scores, the questionnaire was and should be administered at several time points to evaluate withdrawal following benzodiazepine discontinuation.
Two benzodiazepine drugs are approved in the United States for the treatment of LGS: the 1,5-benzodiazepine clobazam and the 1,4- Table 3 Potentially withdrawal-related adverse events (incidence ≥ 2 events overall) following discontinuation of clobazam in multiple-dosage Phase I studies. benzodiazepine clonazepam [11] . While both have been commonly used in treatment regimens for chronic epilepsy [12] , the risk of withdrawal seizures may make cessation of clonazepam therapy difficult and may necessitate use of special epilepsy care units [13] .
There have been few reports of seizure exacerbation with clobazam treatment. One was a case report of a single adult patient who developed negative myoclonic status after withdrawal of clobazam over 6 days [14] . While it is recommended that clobazam be tapered, there may be situations in which inadvertent abrupt clobazam discontinuation can occur. For example, studies have demonstrated that up to 30% of children do not adhere to their AED regimens [15, 16] . In the clobazam OV-1012 study [4] , clobazam was abruptly discontinued over 9 days for one patient as a result of poor compliance. Gastroenteritis, as well as surgical and other procedures, may render oral medications implausible. Finally, serious AEs may require abrupt termination of the medication.
Along with the established long-term efficacy and safety of clobazam for LGS over more than 5 years of therapy [6] , the lack of severe withdrawal-related events, including seizures, even in patients abruptly withdrawn from dosages as great as 160 mg/day, and the absence of any withdrawal-related AEs in patients with epilepsy tapered over a maximum period of 3 weeks support the use of clobazam as chronic therapy for LGS.
Although these results suggest that clobazam has mild withdrawal effects following discontinuation, limitations exist in the overall interpretation of the data. Primarily, the trials were not prospectively designed to assess withdrawal-related AEs following abrupt discontinuation and gradual tapering in similar participant populations. To this point, the Phase I trials consisted of healthy participants, and the Phase II/III trials consisted of patients with LGS. In addition, the results may have been confounded by the close degree of medical monitoring in the setting of a clinical trial, which may over-represent the prevalence and severity of AEs that might be expected after clobazam discontinuation in the clinic. Finally, the potential effects that different durations of clobazam therapy may have had on incidence of potentially withdrawal-related AEs are not clear.
In conclusion, the withdrawal-related AEs observed in the Phase I studies following abrupt clobazam discontinuation were generally mild and comparable those observed for other benzodiazepines. Notably, no withdrawal-related AEs occurred over the 2-to 3-week period during which clobazam dosages were gradually tapered in the Phase II/III studies, which is rapid in comparison with common clinical practice. In the OLE trial, no withdrawal-related AEs have been observed when dosages of clobazam were tapered over 3 weeks, after short-or long-term clobazam use (≤5 years). Data from the Phase I-III studies, including long-term open-label use, and supporting data from legacy psychiatry studies, suggest that clobazam withdrawal-related AEs can readily be avoided with gradual tapering of dosage. Fig. 1 . CIWA-B score ranges after abrupt clobazam discontinuation in Phase I studies. N-values represent the number of clobazam-treated participants in each study. Bars represent minimum and maximum CIWA-B scores in each study. For OV-1022, there were 22 participants with scores N20. Of those 22, 3 had scores N40. For OV-1023, 3 participants had scores N20 (maximum value of 27). For OV-1038, there were 2 participants with scores N20. One participant had a score of 23 and the other had a score of 59. In OV-1022, 6 participants in the moxifloxacin group had scores N20. Of these 6, 2 had scores greater than 40. In the placebo group, 5 participants had scores N20, of which 1 participant had a score N40.
